Table 3:

Linear regression analysis of length of survival by demographic and clinical characteristics of lung cancer patients

Survival Months	Coefficient [95% Confidence Interval]	P>t
Gender
Female vs Male	2.86[95%CI (2.39 – 3.34)]	<0.001
Lung Cancer Stage
Regional vs. Local	-1.73[95%CI (-2.33 – -1.12)]	<0.001
Distance vs. Local	-10.19[95%CI (-10.96 – -9.43)]	<0.001
Un-staged vs. Local	6.98[95%CI (5.3 – 8.67)]	<0.001
Age
60-69 vs. 50-59	-9.12[95%CI (-9.77 – -8.47)]	<0.001
70-79 vs. 50-59	-17.7[95%CI (-18.38 – -17.03)]	<0.001
>79 vs. 50-59	-24.33[95%CI (-25.21 – -23.45)]	<0.001
Race
Black vs. White	-4.06[95%CI (-4.84 – -3.27)]	<0.001
American Indian/Alaska Native vs. White	-5.48[95%CI (-8.89 – -2.07)]	0.002
Asian or Pacific Islander vs. White	-3.49[95%CI (-4.39 – -2.6)]	<0.001
Histology
Adenocarcinoma vs. Other histology	2.89[95%CI (2.23 – 3.55)]	<0.001
Squamous cell carcinoma vs. Other histology	4.36[95%CI (3.58 – 5.14)]	<0.001
Small cell carcinoma vs. Other histology	7.2[95%CI (5.99 – 8.4)]	<0,001
Neoplasm/Malignant vs. Other histology	22.79[95%CI (21.53 – 24.05)]	<0.001
Carcinoma vs. Other histology	4.75[95%CI (2.97 – 6.53)]	<0.001
Large cell carcinoma vs. Other histology	14.08[95%CI (12.34 – 15.82)]	<0.001
Bronchioloalveolar adenocarcinoma vs. Other histology	43.4[95%CI (40.78 – 46.02)]	<0.001
NSCLC vs. Other histology	43.22[95%CI (41.87 – 44.56)]	<0.001
Neuroendocrine carcinoma vs. Other histology	11.2[95%CI (9.06 – 13.33)]	<0.001
Squamous cell carcinoma keratinizing vs. Other histology	2.56[95%CI (0.33 – 4.79)]	0.025
Treatment
Did not receive chemotherapy vs received chemotherapy	-2.43[95%CI (-3.06 – -1.81)]	<0.001
Received radiation vs. did not receive radiation	-0.74[95%CI (-1.39 – -0.1)]	0.023
Did not perform surgery vs performed surgery	-29.5[95%CI (-30.2 – -28.81)]	<0.001